Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Cryomicroneedle Arrays for Biotherapeutics Delivery

Yang C., Zhang L., Zhou A., Wang S., Ren Y., Xiang M.

Narrative Review on Face & Skin, published in Small Sci (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Small Sci (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40837042
PMCID
PMC12362829
DOI
10.1002/smsc.202500009
Citations
2

Abstract (original English)

Biotherapy offers a promising approach for treating a variety of diseases. However, the lack of advanced delivery systems remains a significant barrier to improve the efficacy, safety, and cost-effectiveness of biotherapeutics. The microneedle, as a minimally invasive drug delivery tool, has demonstrated considerable potential in biotherapeutic applications. Despite this promise, challenges remain in fabricating microneedles that effectively preserve the bioactivity of biotherapeutics. Emerging as a novel solution, cryomicroneedles (cryoMNs) employ cryogenically molded ice matrices that exploit phase-transition thermodynamics. The metabolic stasis induced by cryoimmobilization preserves biomolecular conformation and cellular viability. Moreover, the ice-reinforced architectures achieve an optimal balance between mechanical penetration capacity and post-insertion dissolution kinetics, overcoming the rigidity-flexibility trade-off in traditional dissolving microneedles. Current research prioritizes three breakthrough directions: material innovation for cryocompatible polymer-ice interfaces, cold-chain optimization strategies to enhance payload viability, and innovations in medical application scenarios. Notably, preclinical successes in regenerative tissue engineering and thermostable vaccine platforms highlight cryoMNs' potential to bridge precision medicine and global health eq

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research